Chemotherapy and oncolytic virotherapy: Advanced tactics in the war against cancer

Frontiers in Oncology

Volumn 4 JUN, Issue , 2014, Pages

  Nguyen, Andrew ^a   Ho, Louisa ^a   Wan, Yonghong ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Cancer immunotherapy; Cancer vaccines; Combination; Combination therapy; Drug therapy; Oncolytic virotherapy; Oncolytic viruses

Indexed keywords

ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; DOPACHROME TAUTOMERASE; FLUOROURACIL; HISTONE DEACETYLASE; IMMUNOMODULATING AGENT; INTERFERON; ONCOLYTIC VIRUS; SUNITINIB; TRICHOSTATIN A; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; DNA DAMAGE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; NEOPLASM; NONHUMAN; ONCOLYTIC VIROTHERAPY; REVIEW; TUMOR INVASION; TUMOR MICROENVIRONMENT; VESICULAR STOMATITIS VIRUS; VIRAL TROPISM; VIRUS REPLICATION;

EID: 84904694379     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00145     Document Type: Review

References (171)

1. Pol J. Oncolytic viruses: a step into cancer immunotherapy. Virus Adapt Treat (2012) 4:1-21. doi: 10.2147/VAAT.S12980
2. Atherton MJ, Lichty BD. Evolution of oncolytic viruses: novel strategies for cancer treatment. Immunotherapy (2013) 5(11):1191-206. doi:10.2217/imt.13.123
3. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology (2013) 2(6):e24612. doi:10.4161/onci.24612
4. Patel MR, Kratzke RA. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res (2013) 161(4):355-64. doi:10.1016/j.trsl.2012.12.010
5. Buonaguro FM, Tornesello ML, Izzo F, Buonaguro L. Oncolytic virus therapies. Pharm Pat Anal (2012) 1(5):621-7. doi:10.4155/ppa.12.65
6. Moerdyk-Schauwecker M, Shah NR, Murphy AM, Hastie E, Mukherjee P, Grdzelishvili VZ. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology (2013) 436(1):221-34. doi:10.1016/j.virol.2012.11.014
7. Forbes NE, Abdelbary H, Lupien M, Bell JC, Diallo JS. Exploiting tumor epigenetics to improve oncolytic virotherapy. Front Genet (2013) 4:184. doi:10.3389/fgene.2013.00184
8. Wennier ST, Liu J, McFadden G. Bugs and drugs: oncolytic virotherapy in combination with chemotherapy. Curr Pharm Biotechnol (2012) 13(9):1817-33. doi:10.2174/138920112800958850
9. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther (2010) 18(2):251-63. doi:10.1038/mt.2009.283
10. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell (1989) 56(5):855-65. doi:10.1016/0092-8674(89)90690-9
11. Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol (2004) 6(3):208-17. doi:10.1215/S1152851703000577
12. Berno V, Porrini D, Castiglioni F, Campiglio M, Casalini P, Pupa SM, et al. The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. Endocr Relat Cancer (2005) 12(2):393-406. doi:10.1677/erc.1.00870
13. Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A (2013) 110(18):7306-11. doi:10.1073/pnas.1214441110
14. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol (2006) 80(11):5145-55. doi:10.1128/JVI.02618-05
15. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 6(7):821-5. doi:10.1038/77558
16. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 4(4):263-75. doi:10.1016/S1535-6108(03)00241-1
17. Noser JA, Mael AA, Sakuma R, Ohmine S, Marcato P, Lee PW, et al. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther (2007) 15(8):1531-6. doi:10.1038/sj.mt.6300193
18. Wollmann G, Davis JN, Bosenberg MW, Van Den Pol AN. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes. J Virol (2013) 87(12):6644-59. doi:10.1128/JVI.03311-12
19. Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev (2010) 21(2-3):185-95. doi:10.1016/j.cytogfr.2010.02.011
20. Mansour M, Palese P, Zamarin D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol (2011) 85(12):6015-23. doi:10.1128/JVI.01537-10
21. Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther (2002) 13(4):485-95. doi:10.1089/10430340252809784
22. Fukuda K, Abei M, Ugai H, Seo E, Wakayama M, Murata T, et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res (2003) 63(15):4434-40.
23. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene (2005) 24(52):7775-91. doi:10.1038/sj.onc.1209044
24. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res (2004) 10(16):5299-312. doi:10.1158/1078-0432.CCR-0349-03
25. Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res (2007) 67(18):8783-90. doi:10.1158/0008-5472.CAN-07-0357
26. Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W, et al. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther (2006) 13(11):1011-22. doi:10.1038/sj.cgt.7700969
27. Sathaiah M, Thirunavukkarasu P, O'Malley ME, Kavanagh MA, Ravindranathan R, Austin F, et al. Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer. Cancer Gene Ther (2012) 19(3):192-201. doi:10.1038/cgt.2011.77
28. van Beusechem VW, Van Den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res (2002) 62(21):6165-71.
29. Ma J, He X, Wang W, Huang Y, Chen L, Cong W, et al. E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer. Dig Dis Sci (2009) 54(7):1425-31. doi:10.1007/s10620-008-0543-0
30. Fang L, Cheng Q, Li W, Liu J, Li L, Xu K, et al. Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells. Virus Res (2014) 181:61-71. doi:10.1016/j.virusres.2013.12.021
31. Li Y, Zhang B, Zhang H, Zhu X, Feng D, Zhang D, et al. Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth. J Cancer Res Clin Oncol (2013) 139(6):933-41. doi:10.1007/s00432-013-1406-4
32. Meng S, Xu J, Wu Y, Ding C. Targeting autophagy to enhance oncolytic virus-based cancer therapy. Expert Opin Biol Ther (2013) 13(6):863-73. doi:10.1517/14712598.2013.774365
33. McFarlane S, Aitken J, Sutherland JS, Nicholl MJ, Preston VG, Preston CM. Early induction of autophagy in human fibroblasts after infection with human cytomegalovirus or herpes simplex virus 1. J Virol (2011) 85(9):4212-21. doi:10.1128/JVI.02435-10
34. Rodriguez-Rocha H, Gomez-Gutierrez JG, Garcia-Garcia A, Rao XM, Chen L, McMasters KM, et al. Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology (2011) 416(1-2):9-15. doi:10.1016/j.virol.2011.04.017
35. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, et al. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther (2008) 16(3):487-93. doi:10.1038/sj.mt.6300400
36. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst (2007) 99(18):1410-4. doi:10.1093/jnci/djm102
37. Colunga AG, Laing JM, Aurelian L. The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Gene Ther (2010) 17(3):315-27. doi:10.1038/gt.2009.126
38. Ito H, Aoki H, Kuhnel F, Kondo Y, Kubicka S, Wirth T, et al. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst (2006) 98(9):625-36. doi:10.1093/jnci/djj161
39. Botta G, Passaro C, Libertini S, Abagnale A, Barbato S, Maione AS, et al. Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo. Hum Gene Ther (2012) 23(6):623-34. doi:10.1089/hum.2011.120
40. Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, et al. Targeting tumor vasculature with an oncolytic virus. Mol Ther (2011) 19(5):886-94. doi:10.1038/mt.2011.26
41. Hou W, Chen H, Rojas J, Sampath P, Thorne SH. Oncolytic vaccinia virus demonstrates anti-angiogenic effects mediated by targeting of VEGF. Int J Cancer (2014). doi:10.1002/ijc.28747
42. Edukulla R, Woller N, Mundt B, Knocke S, Gurlevik E, Saborowski M, et al. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res (2009) 69(4):1448-58. doi:10.1158/0008-5472.CAN-08-1160
43. Endo Y, Sakai R, Ouchi M, Onimatsu H, Hioki M, Kagawa S, et al. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene (2008) 27(17):2375-81. doi:10.1038/sj.onc.1210884
44. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 19(6):1008-16. doi:10.1038/mt.2011.65
45. Bridle BW, Hanson S, Lichty BD. Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev (2010) 21(2-3):143-8. doi:10.1016/j.cytogfr.2010.02.009
46. Wong RJ, Chan MK, Yu Z, Kim TH, Bhargava A, Stiles BM, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res (2004) 10(1 Pt 1):251-9. doi:10.1158/1078-0432.CCR-0197-3
47. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res (2007) 67(17):8285-92. doi:10.1158/0008-5472.CAN-07-1025
48. Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z, et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res (2007) 67(14):6872-81. doi:10.1158/0008-5472.CAN-06-3244
49. Choi IK, Lee JS, Zhang SN, Park J, Sonn CH, Lee KM, et al. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rbeta2 or IL-18Ralpha. Gene Ther (2011) 18(9):898-909. doi:10.1038/gt.2011.37
50. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 70(11):4297-309. doi:10.1158/0008-5472.CAN-09-3567
51. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther (2010) 18(10):1874-84. doi:10.1038/mt.2010.161
52. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 27(34):5763-71. doi:10.1200/JCO.2009.24.3675
53. Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol (2010) 6(6):941-9. doi:10.2217/fon.10.66
54. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 19(3):329-36. doi:10.1038/nm.3089
55. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther (2006) 14(3):361-70. doi:10.1016/j.ymthe.2006.05.008
56. Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res (2013) 19(10):2734-44. doi:10.1158/1078-0432.CCR-12-2546
57. Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med (2013) 5(185):185ra63. doi:10.1126/scitranslmed.3005361
58. Dong J, McPherson CM, Stambrook PJ. Flt-3 ligand: a potent dendritic cell stimulator and novel antitumor agent. Cancer Biol Ther (2002) 1(5):486-9. doi:10.4161/cbt.1.5.161
59. Bernt KM, Ni S, Tieu AT, Lieber A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res (2005) 65(10):4343-52. doi:10.1158/0008-5472.CAN-04-3527
60. Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, et al. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery (2012) 71(3):741-8. doi:10.1227/NEU.0b013e318260fd73 discussion 8
61. Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther (2011) 19(4):650-7. doi:10.1038/mt.2010.312
62. Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, et al. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother (2009) 32(2):145-56. doi:10.1097/CJI.0b013e318193d31e
63. Li J, O'Malley M, Sampath P, Kalinski P, Bartlett DL, Thorne SH. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia (2012) 14(12):1115-21.
64. Reichel CA, Puhr-Westerheide D, Zuchtriegel G, Uhl B, Berberich N, Zahler S, et al. C-C motif chemokine CCL3 and canonical neutrophil attractants promote neutrophil extravasation through common and distinct mechanisms. Blood (2012) 120(4):880-90. doi:10.1182/blood-2012-01-402164
65. Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, Nowicki MO, et al. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J Virol (2012) 86(8):4566-77. doi:10.1128/JVI.05545-11
66. Bhat R, Dempe S, Dinsart C, Rommelaere J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer (2011) 128(4):908-19. doi:10.1002/ijc.25415
67. Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, et al. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther (2010) 21(4):439-50. doi:10.1089/hum.2009.143
68. Feder-Mengus C, Schultz-Thater E, Oertli D, Marti WR, Heberer M, Spagnoli GC, et al. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses. Hum Gene Ther (2005) 16(3):348-60. doi:10.1089/hum.2005.16.348
69. Huang XF, Ren W, Rollins L, Pittman P, Shah M, Shen L, et al. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res (2003) 63(21):7321-9.
70. Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 18(8):1430-9. doi:10.1038/mt.2010.98
71. Granot T, Yamanashi Y, Meruelo D. Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8(+) T-cell immunity. Mol Ther (2014) 22(1):112-22. doi:10.1038/mt.2013.215
72. Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, et al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res (2009) 69(19):7713-20. doi:10.1158/0008-5472.CAN-09-1013
73. Wongthida P, Diaz RM, Pulido C, Rommelfanger D, Galivo F, Kaluza K, et al. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther (2011) 22(11):1343-53. doi:10.1089/hum.2010.216
74. Rommelfanger DM, Wongthida P, Diaz RM, Kaluza KM, Thompson JM, Kottke TJ, et al. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res (2012) 72(18):4753-64. doi:10.1158/0008-5472.CAN-12-0600
75. Humphries C. Adoptive cell therapy: honing that killer instinct. Nature (2013) 504(7480):S13-5. doi:10.1038/504S13a
76. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett (2007) 254(2):178-216. doi:10.1016/j.canlet.2007.02.002
77. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol (2012) 30(7):658-70. doi:10.1038/nbt.2287
78. Romagnani C, Della Chiesa M, Kohler S, Moewes B, Radbruch A, Moretta L, et al. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol (2005) 35(8):2452-8. doi:10.1002/eji.200526069
79. Dorner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunity (2007) 27(3):384-92. doi:10.1016/j.immuni.2007.09.002
80. Stoermer KA, Morrison TE. Complement and viral pathogenesis. Virology (2011) 411(2):362-73. doi:10.1016/j.virol.2010.12.045
81. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther (2001) 8(5):341-8. doi:10.1038/sj.gt.3301389
82. Massari I, Donnini A, Argentati K, Straino S, Mangoni A, Gaetano C, et al. Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats. Exp Gerontol (2002) 37(6):823-31. doi:10.1016/S0531-5565(02)00011-6
83. Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN, et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 74(10):4765-75. doi:10.1128/JVI.74.10.4765-4775.2000
84. Pensiero MN, Wysocki CA, Nader K, Kikuchi GE. Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum Gene Ther (1996) 7(9):1095-101. doi:10.1089/hum.1996.7.9-1095
85. Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology (2013) 2(8):e25961. doi:10.4161/onci.25961
86. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 419(6908):734-8. doi:10.1038/nature01112
87. Groh V, Smythe K, Dai Z, Spies T. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol (2006) 7(7):755-62. doi:10.1038/ni0906-1004a
88. Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol (2002) 12(1):43-50. doi:10.1006/scbi.2001.0402
89. Palazon A, Aragones J, Morales-Kastresana A, de Landazuri MO, Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2012) 18(5):1207-13. doi:10.1158/1078-0432.CCR-11-1591
90. Mendler AN, Hu B, Prinz PU, Kreutz M, Gottfried E, Noessner E. Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int J Cancer (2012) 131(3):633-40. doi:10.1002/ijc.26410
91. Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, et al. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res (2010) 70(2):598-608. doi:10.1158/0008-5472.CAN-09-1510
92. Smyth JW, Fleeton MN, Sheahan BJ, Atkins GJ. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Ther (2005) 12(2):147-59. doi:10.1038/sj.gt.3302390
93. Vaha-Koskela MJ, Kallio JP, Jansson LC, Heikkila JE, Zakhartchenko VA, Kallajoki MA, et al. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res (2006) 66(14):7185-94. doi:10.1158/0008-5472.CAN-05-2214
94. Cordaro TA, de Visser KE, Tirion FH, Graus YM, Haanen JB, Kioussis D, et al. Tumor size at the time of adoptive transfer determines whether tumor rejection occurs. Eur J Immunol (2000) 30(5):1297-307. doi:10.1002/(SICI)1521-4141(200005)30:5<1297::AID-IMMU1297>3.0.CO;2-C
95. Li ZY, Ni S, Yang X, Kiviat N, Lieber A. Xenograft models for liver metastasis: relationship between tumor morphology and adenovirus vector transduction. Mol Ther (2004) 9(5):650-7. doi:10.1016/j.ymthe.2004.01.021
96. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res (2000) 60(15):4251-5.
97. Bilbao R, Bustos M, Alzuguren P, Pajares MJ, Drozdzik M, Qian C, et al. A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. Gene Ther (2000) 7(21):1824-32. doi:10.1038/sj.gt.3301312
98. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res (2006) 4(2):61-70. doi:10.1158/1541-7786.MCR-06-0002
99. Alain T, Kim M, Johnston RN, Urbanski S, Kossakowska AE, Forsyth PA, et al. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Br J Cancer (2006) 95(8):1020-7. doi:10.1038/sj.bjc.6603363
100. Kim YT, Ganly I, Brown R, Stuart D. Acquired resistance to cytolysis of the E1B-attenuated adenovirus, dl1520, in ovarian tumour cell lines. Cancer Gene Ther (2003) 10(8):589-90.
101. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 12(6):385-92. doi:10.1038/nrm3115
102. Nguyen TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS, et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A (2008) 105(39):14981-6. doi:10.1073/pnas.0803988105
103. Diallo JS, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther (2010) 18(6):1123-9. doi:10.1038/mt.2010.67
104. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res (2003) 63(2):348-53.
105. Smakman N, van der Bilt JD, Van Den Wollenberg DJ, Hoeben RC, Borel Rinkes IH, Kranenburg O. Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther (2006) 13(8):815-8.
106. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 5(8):881-7. doi:10.1038/11320
107. Kambara H, Saeki Y, Chiocca EA. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res (2005) 65(24):11255-8. doi:10.1158/0008-5472.CAN-05-2278
108. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther (2008) 16(10):1665-73. doi:10.1038/mt.2008.162
109. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Parker WB, Sorscher EJ, et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther (2007) 15(11):1991-7. doi:10.1038/sj.mt.6300291
110. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res (2008) 14(1):259-69. doi:10.1158/1078-0432.CCR-07-1510
111. Kottke T, Thompson J, Diaz RM, Pulido J, Willmon C, Coffey M, et al. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res (2009) 15(2):561-9. doi:10.1158/1078-0432.CCR-08-1688
112. Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res (2009) 15(8):2777-88. doi:10.1158/1078-0432.CCR-08-2342
113. Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res (2009) 69(21):8516-25. doi:10.1158/0008-5472.CAN-09-2522
114. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 34(2):336-44. doi:10.1002/eji.200324181
115. Tseng CW, Hung CF, Alvarez RD, Trimble C, Huh WK, Kim D, et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 14(10):3185-92. doi:10.1158/1078-0432.CCR-08-0037
116. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2005) 105(7):2862-8. doi:10.1182/blood-2004-06-2410
117. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 201(10):1591-602. doi:10.1084/jem.20042167
118. Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L, et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol (2008) 129(2):219-29. doi:10.1016/j.clim.2008.07.013
119. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood (2005) 106(6):2018-25. doi:10.1182/blood-2005-02-0642
120. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother (2009) 58(10):1627-34. doi:10.1007/s00262-009-0671-1
121. Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, Chiang YC, et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther (2010) 18(6):1233-43. doi:10.1038/mt.2010.34
122. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res (2003) 63(23):8408-13.
123. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2007) 56(5):641-8. doi:10.1007/s00262-006-0225-8
124. Kottke T, Galivo F, Wongthida P, Diaz RM, Thompson J, Jevremovic D, et al. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther (2008) 16(7):1217-26. doi:10.1038/mt.2008.83
125. Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther (2011) 19(9):1737-46. doi:10.1038/mt.2011.113
126. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9(3):162-74. doi:10.1038/nri2506
127. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res (2008) 68(13):5439-49. doi:10.1158/0008-5472.CAN-07-6621
128. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 179(2):977-83. doi:10.4049/jimmunol.179.2.977
129. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 66(2):1123-31. doi:10.1158/0008-5472.CAN-05-1299
130. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 11(18):6713-21. doi:10.1158/1078-0432.CCR-05-0883
131. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 70(9):3526-36. doi:10.1158/0008-5472.CAN-09-3278
132. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res (2010) 70(8):3052-61. doi:10.1158/0008-5472.CAN-09-3690
133. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res (2010) 16(18):4583-94. doi:10.1158/1078-0432.CCR-10-0733
134. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res (2003) 63(15):4441-9.
135. Esaki S, Goshima F, Kimura H, Murakami S, Nishiyama Y. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models. Int J Cancer (2013) 132(7):1592-601. doi:10.1002/ijc.27823
136. Takehara Y, Satoh T, Nishizawa A, Saeki K, Nakamura M, Masuzawa M, et al. Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma. Clin Immunol (2013) 149(1):1-10. doi:10.1016/j.clim.2013.05.019
137. Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Hallden G. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer Gene Ther (2011) 18(10):734-43. doi:10.1038/cgt.2011.45
138. Jha BK, Dong B, Nguyen CT, Polyakova I, Silverman RH. Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy. Mol Ther (2013) 21(9):1749-57. doi:10.1038/mt.2013.112
139. Kulu Y, Kawasaki H, Donahue JM, Kasuya H, Cusack JC, Choi EW, et al. Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis. Cancer Gene Ther (2013) 20(2):133-40. doi:10.1038/cgt.2012.97
140. Kaneno R, Shurin GV, Kaneno FM, Naiditch H, Luo J, Shurin MR. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol (Dordr) (2011) 34(2):97-106. doi:10.1007/s13402-010-0005-5
141. Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG, et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer (2003) 104(4):437-45. doi:10.1002/ijc.10969
142. Adair SJ, Hogan KT. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother (2009) 58(4):589-601. doi:10.1007/s00262-008-0582-6
143. Fonsatti E, Nicolay HJ, Sigalotti L, Calabro L, Pezzani L, Colizzi F, et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res (2007) 13(11):3333-8. doi:10.1158/1078-0432.CCR-06-3091
144. Donepudi M, Raychaudhuri P, Bluestone JA, Mokyr MB. Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells. J Immunol (2001) 166(11):6491-9. doi:10.4049/jimmunol.166.11.6491
145. Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol (2000) 164(12):6230-6. doi:10.4049/jimmunol.164.12.6230
146. Vereecque R, Saudemont A, Quesnel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia (2004) 18(7):1223-30. doi:10.1038/sj.leu.2403391
147. Ghebeh H, Lehe C, Barhoush E, Al-Romaih K, Tulbah A, Al-Alwan M, et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res (2010) 12(4):R48. doi:10.1186/bcr2605
148. van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One (2009) 4(9):e6982. doi:10.1371/journal.pone.0006982
149. Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J Immunol (2004) 172(7):4599-608. doi:10.4049/jimmunol.172.7.4599
150. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 477(7362):99-102. doi:10.1038/nature10358
151. Sobol PT, Boudreau JE, Stephenson K, Wan Y, Lichty BD, Mossman KL. Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther (2011) 19(2):335-44. doi:10.1038/mt.2010.264
152. Stanford MM, Barrett JW, Nazarian SH, Werden S, McFadden G. Oncolytic virotherapy synergism with signaling inhibitors: rapamycin increases myxoma virus tropism for human tumor cells. J Virol (2007) 81(3):1251-60. doi:10.1128/JVI.01408-06
153. Homicsko K, Lukashev A, Iggo RD. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res (2005) 65(15):6882-90. doi:10.1158/0008-5472.CAN-05-0309
154. Chen W, Ma T, Shen XN, Xia XF, Xu GD, Bai XL, et al. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res (2012) 72(6):1363-72. doi:10.1158/0008-5472.CAN-11-2684
155. Khan AN, Magner WJ, Tomasi TB. An epigenetic vaccine model active in the prevention and treatment of melanoma. J Transl Med (2007) 5:64. doi:10.1186/1479-5876-5-64
156. Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA, et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther (2008) 16(9):1546-55. doi:10.1038/mt.2008.155
157. Katsura T, Iwai S, Ota Y, Shimizu H, Ikuta K, Yura Y. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther (2009) 16(3):237-45. doi:10.1038/cgt.2008.81
158. MacTavish H, Diallo JS, Huang B, Stanford M, Le Boeuf F, De Silva N, et al. Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One (2010) 5(12):e14462. doi:10.1371/journal.pone.0014462
159. Genin P, Morin P, Civas A. Impairment of interferon-induced IRF-7 gene expression due to inhibition of ISGF3 formation by trichostatin A. J Virol (2003) 77(12):7113-9. doi:10.1128/JVI.77.12.7113-7119.2003
160. Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther (2008) 16(6):1041-7. doi:10.1038/mt.2008.58
161. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res (2009) 69(6):2506-13. doi:10.1158/0008-5472.CAN-08-4323
162. Kottke T, Hall G, Pulido J, Diaz RM, Thompson J, Chong H, et al. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest (2010) 120(5):1551-60. doi:10.1172/JCI41431
163. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 46(12 Pt 1):6387-92.
164. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev (2011) 63(3):136-51. doi:10.1016/j.addr.2010.04.009
165. Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res (2007) 67(2):440-4. doi:10.1158/0008-5472.CAN-06-3145
166. Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 12(1):103. doi:10.1186/1476-4598-12-103
167. Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther (2008) 8(10):1581-8. doi:10.1586/14737140.8.10.1581
168. Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK, et al. 5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg (2005) 9(8):1068-77. doi:10.1016/j.gassur.2005.06.024 discussion 77-9
169. Braidwood LGS, Graham A, Conner J. Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs. Oncolytic Virother (2013) 2:57-74. doi:10.2147/OV.S52601
170. Eshun FK, Currier MA, Gillespie RA, Fitzpatrick JL, Baird WH, Cripe TP. VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy. Gene Ther (2010) 17(7):922-9. doi:10.1038/gt.2010.82
171. Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther (2013) 21(4):887-94. doi:10.1038/mt.2012.265